Evidence map›Paper›PMID 35275911›Full record

ArticlePLoS neglected tropical diseases2022

Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data.

Christine Tedijanto, Solomon Aragie, Zerihun Tadesse, Mahteme Haile, Taye Zeru, Scott D Nash, Dionna M Wittberg, Sarah Gwyn, Diana L Martin, Hugh J W Sturrock and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Monitoring transmission intensity of trachoma with serology.medRxiv : the preprint server for health sciences · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Christine TedijantoFrancis I. Proctor Foundation, University of California, San Francisco, California, United States of America.ORCID 0000-0003-3403-5765
Solomon AragieThe Carter Center Ethiopia, Addis Ababa, Ethiopia.ORCID 0000-0003-4967-9627
Zerihun TadesseThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Mahteme HaileAmhara Public Health Institute, Bahir Dar, Ethiopia.ORCID 0000-0001-9996-6742
Taye ZeruAmhara Public Health Institute, Bahir Dar, Ethiopia.
Scott D NashThe Carter Center, Atlanta, Georgia, United States of America.ORCID 0000-0001-5741-8537
Dionna M WittbergFrancis I. Proctor Foundation, University of California, San Francisco, California, United States of America.
Sarah GwynDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Diana L MartinDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Hugh J W SturrockLocational, Poole, United Kingdom.
Thomas M LietmanFrancis I. Proctor Foundation, University of California, San Francisco, California, United States of America.
Jeremy D KeenanFrancis I. Proctor Foundation, University of California, San Francisco, California, United States of America.ORCID 0000-0002-7118-1457
Benjamin F ArnoldFrancis I. Proctor Foundation, University of California, San Francisco, California, United States of America.ORCID 0000-0001-6105-7295
University of California, San Francisco · USCenters for Disease Control and Prevention · USEthiopian Public Health Institute · ETThe Carter Center · ETCarter Center · USPoole Hospital · GB

Funding

Sanitation, Water, and Instruction in face-washing for trachoma II (SWIFT II)UG1EY023939 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID · 2019 to 2023
$4.1M
Sanitation, Water, and Instruction in Face-washing for TrachomaU10EY023939 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID · 2014 to 2018
$2.7M
Seroepidemiology of trachoma for the elimination endgameR01AI158884 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARNOLD, BENJAMIN F · 2021 to 2025
$2.0M
Seroepidemiologic methods to identify hotspots of trachoma and predict future infectionR03AI147128 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARNOLD, BENJAMIN F · 2019 to 2020
$175k
NEI NIH HHS U10 EY023939NEI NIH HHS UG1 EY023939NIAID NIH HHS R01 AI158884NIAID NIH HHS R03 AI147128
6 · The paper itself

Abstract

Trachoma is an infectious disease characterized by repeated exposures to Chlamydia trachomatis (Ct) that may ultimately lead to blindness. Efficient identification of communities with high infection burden could help target more intensive control efforts. We hypothesized that IgG seroprevalence in combination with geospatial layers, machine learning, and model-based geostatistics would be able to accurately predict future community-level ocular Ct infections detected by PCR. We used measurements from 40 communities in the hyperendemic Amhara region of Ethiopia to assess this hypothesis. Median Ct infection prevalence among children 0-5 years old increased from 6% at enrollment, in the context of recent mass drug administration (MDA), to 29% by month 36, following three years without MDA. At baseline, correlation between seroprevalence and Ct infection was stronger among children 0-5 years old (ρ = 0.77) than children 6-9 years old (ρ = 0.48), and stronger than the correlation between active trachoma and Ct infection (0-5y ρ = 0.56; 6-9y ρ = 0.40). Seroprevalence was the strongest concurrent predictor of infection prevalence at month 36 among children 0-5 years old (cross-validated R2 = 0.75, 95% CI: 0.58-0.85), though predictive performance declined substantially with increasing temporal lag between predictor and outcome measurements. Geospatial variables, a spatial Gaussian process, and stacked ensemble machine learning did not meaningfully improve predictions. Serological markers among children 0-5 years old may be an objective tool for identifying communities with high levels of ocular Ct infections, but accurate, future prediction in the context of changing transmission remains an open challenge.

Indexed as

TrachomaAnti-Bacterial AgentsAzithromycinChildChild, PreschoolChlamydia trachomatisEthiopiaHumansInfantInfant, NewbornPrevalenceSeroepidemiologic StudiesAnti-Bacterial AgentsAzithromycin

Identifiers

PMID35275911
PMCPMC8942265
OpenAlexW4220984721

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.